AbbVie Inc., through its subsidiary Allergan Aesthetics, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental premarket approval application for SKINVIVE by JUVÉDERM®. This application seeks to expand the indication of SKINVIVE to include the reduction of neck lines, aiming to improve neck appearance. Already approved in the U.S. for enhancing cheek skin smoothness in adults over 21, SKINVIVE by JUVÉDERM® could become the first hyaluronic acid injectable treatment option targeting neck lines if approved. The application is supported by a clinical study that met all primary and secondary endpoints.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.